PMV Pharmaceuticals, Inc. — Form 8-K Summary
Reporting/event date: October 1, 2026; the report was signed and the related press release issued October 5, 2026. This filing reports a director appointment, not quarterly or annual financial results.
Business context and key event
PMV Pharmaceuticals appointed Dr. Matthew Eckler to its board of directors effective October 1, 2026. His term expires at the Company’s 2029 Annual Meeting of Stockholders. Eckler has served as a principal at Samsara BioCapital since May 2025 and previously worked as a healthcare investor at ArrowMark Partners.
Compensation and other disclosures
- Under the Company’s outside director compensation policy, Eckler is eligible for $40,000 in annual cash compensation, plus additional cash compensation for committee service.
- He received an initial stock option award for 84,000 shares, granted on the first trading date on or after his appointment. He is expected to receive annual options for 42,000 shares on the date of each annual stockholders’ meeting, consistent with the policy.
- The Company entered into its standard indemnification agreement with Eckler. The filing reports no appointment-related arrangements with other persons, no family relationships with Company directors or executive officers, and no other material transaction requiring disclosure under Item 404(a).
Financial performance, outlook, and risks
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or operating outlook figures. It does not describe new contingencies or business risks.
Important facts for investors to verify
- The terms and vesting conditions of the 84,000-share initial option award and any future annual awards.
- Any additional compensation associated with committee assignments.
- The October 5, 2026 press release furnished as Exhibit 99.1; the filing states that the press release information is furnished, not filed for Section 18 purposes, unless specifically incorporated by reference.